Spyre Therapeutics (SYRE) insider trading in the last 6 months

Form 4 filings, newest first

Quality Score today 7

2 insiders sold $401M. No buys.

SellScott L. Burrows$871KChief Financial Officerat $87.14 on Jun 25, filed Jun 26

SellScott L. BurrowsChief Financial Officer$871Kat $87.14 on Jun 25, filed Jun 26

SellScott L. Burrows$436KChief Financial Officerat $87.12 on Jun 25, filed Jun 26

SellScott L. BurrowsChief Financial Officer$436Kat $87.12 on Jun 25, filed Jun 26

SellFairmount Funds Management LLC$400MDirectorat $85.31 on Jun 23, filed Jun 23

SellFairmount Funds Management LLCDirector$400Mat $85.31 on Jun 23, filed Jun 23

From SEC Form 4s, the newest filed Jun 26, 2026 · Insiders have 2 business days to file a trade

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

See all 3 tradesSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Pro members see every filing on SYRE with what each insider bought or sold and at what price, and can turn on an optional alert when an insider buys.

Who files at Spyre Therapeutics

Scott L. BurrowsChief Financial Officer · 2 sales

Insider trades by person

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Questions about SYRE's insider trades

As of Nov 2, 2026: Spyre Therapeutics (SYRE) has 3 insider filings on record in the last 6 months, the newest filed Jun 26, 2026. Its Quality Score is 7 (Average). Scores as of 9:30 PM ET, 15 minutes behind.

Are SYRE insiders buying or selling?

2 insiders sold $401M across 3 filings in the last 6 months. No open-⁠market buys on record. The newest filing: Scott L. Burrows, Chief Financial Officer, sold $871K on Jun 25, 2026.

Who are SYRE's biggest insider sellers?

By the dollars of their sales in the last 6 months: Fairmount Funds Management LLC (Director), 1 sale; Scott L. Burrows (Chief Financial Officer), 2 sales.

When did an SYRE insider last buy?

No SYRE insider bought shares on the open market in the last 6 months, as filed on Form 4. The newest filing is a sale by Scott L. Burrows on Jun 25, 2026.

Spyre Therapeutics's page has its Quality Score, its chart, and its earnings. More in Healthcare and Biotech.